Nu-Med Plus (NUMD) Capital Expenditures (2012 - 2018)

Nu-Med Plus' (NUMD) quarterly Capital Expenditures came in at $1.0 in Q4 2018, up 100.09% quarter-over-quarter from -$1101.0 in Q4 2014.

Nu-Med Plus (NUMD) Capital Expenditures (2012 - 2018) Analysis & Trends

Nu-Med Plus has disclosed Capital Expenditures across 4 years of filings, most recently posting $1.0 for Q4 2018.

Capital Expenditures for Q4 2018 came in at $1.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2019 was $1.0 (changed 0.0% YoY), and the FY2018 annual result was -$5025.0, changed N/A from the prior year.
Capital Expenditures came in at $1.0 for Q4 2018 at Nu-Med Plus, up from -$1101.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $1.0 in Q4 2018 to a low of -$1101.0 in Q4 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Abbott Laboratories	152.92 Bn	146.27 Bn	6.27 Bn	399.00 Mn
2	Stryker	119.50 Bn	116.62 Bn	3.81 Bn	166.00 Mn
3	Medtronic	102.71 Bn	94.54 Bn	5.76 Bn	444.00 Mn
4	Boston Scientific	69.72 Bn	68.51 Bn	3.61 Bn	177.00 Mn
5	Edwards Lifesciences	49.24 Bn	45.57 Bn	1.29 Bn	64.90 Mn
6	GE HealthCare Technologies	29.74 Bn	27.67 Bn	1.98 Bn	86.00 Mn
7	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	-85.46 Mn
8	Dexcom	28.96 Bn	27.84 Bn	750.30 Mn	76.60 Mn
9	Steris	20.31 Bn	19.88 Bn	697.10 Mn	90.20 Mn
10	Nu-Med Plus	-	-	-	-

Download Data